Puberty can be medically delayed using medications called GnRH agonists, which temporarily pause the hormonal signals that drive sexual development. These medications are FDA-approved for children with precocious puberty (puberty starting before age 8 in girls or 9 in boys) and are also used as part of gender-affirming care for transgender and gender diverse adolescents. In both cases, treatment requires evaluation by a pediatric endocrinologist and ongoing monitoring.
Why Puberty Is Sometimes Delayed
There are two main reasons a doctor might recommend pausing puberty. The first is precocious puberty, where a child’s body begins developing years earlier than expected. Early puberty can cause emotional distress, social challenges, and a significant reduction in adult height because the growth plates in bones close prematurely. The second reason is gender dysphoria, where an adolescent experiences marked, sustained distress because their body is developing in ways that don’t align with their gender identity.
For precocious puberty, the goal is to halt development until the child reaches a more typical age, protecting both their emotional wellbeing and their growth potential. Research on girls with central precocious puberty found that treatment produced an average height gain of about 3.4 cm over what was predicted without intervention. The benefit was even larger for girls whose bone age was more than two years ahead of their actual age, with gains averaging 5.3 cm.
For gender diverse adolescents, international clinical guidelines recommend that puberty suppression begin only after the first physical signs of puberty have appeared (Tanner stage 2, meaning early breast budding or testicular enlargement). The adolescent must also meet specific criteria: a sustained experience of gender incongruence, the emotional maturity to participate in informed consent, and a clear understanding of the treatment’s effects on fertility.
How Puberty Blockers Work
Your body naturally triggers puberty through pulses of a hormone called GnRH, released from the brain in rhythmic bursts. These pulses tell the pituitary gland to release two other hormones that activate the ovaries or testes. GnRH agonist medications mimic this hormone but deliver it continuously rather than in pulses. Within minutes, that constant flood overwhelms the pituitary gland’s receptors, and the gland essentially stops responding. Without signals from the pituitary, the ovaries or testes stop producing estrogen or testosterone, and puberty stalls.
This mechanism is the key to understanding why the treatment is reversible. The medications don’t alter the underlying biology of the reproductive system. They simply keep it on pause by suppressing the signal chain.
Types of Treatment
Five GnRH agonists are currently FDA-approved for central precocious puberty in the United States, and they differ mainly in how they’re given and how often.
- Monthly injection: Leuprolide acetate (Lupron Depot-Ped), given as an intramuscular shot every four weeks.
- Three-month injection: A longer-acting form of leuprolide acetate, injected every 12 weeks.
- Six-month injection (intramuscular): Triptorelin pamoate (Triptodur), injected every 24 weeks.
- Six-month injection (subcutaneous): Leuprolide acetate (Fensolvi), a under-the-skin injection every 24 weeks.
- Yearly implant: Histrelin acetate (Supprelin LA), a small rod placed under the skin of the upper arm during a minor surgical procedure, replaced once a year.
The implant tends to provide the most consistent hormone suppression since it releases medication steadily rather than in a cycle that peaks and fades. The six-month options reduce the number of clinic visits. Your child’s endocrinologist will recommend a specific option based on the child’s age, comfort with injections, and how reliably the family can keep appointment schedules.
What Monitoring Looks Like
Once treatment starts, the medical team checks that puberty is actually being suppressed. Blood draws every 6 to 12 months measure levels of the key reproductive hormones (LH, FSH, and either estrogen or testosterone) to confirm they’ve dropped to prepubertal levels. Vitamin D is also checked regularly because of its role in bone health.
Bone density scans are recommended at the start of treatment and then every one to two years for as long as suppression continues, and ideally until the mid-20s when bone mass typically peaks. If cardiovascular risk factors are present, doctors may also monitor blood sugar, cholesterol, and other metabolic markers.
Effects on Bone Health
This is one of the most important considerations with puberty blockers. Sex hormones play a central role in building bone density during adolescence, so pausing them means bones don’t accumulate mineral at the expected rate. Studies consistently show that bone density scores decline during treatment, particularly in the lower spine, and the decline continues for as long as suppression lasts rather than leveling off after the first year.
The good news is that bone density partially recovers once sex hormones are introduced, either through natural puberty resuming or through hormone therapy. However, recovery may not be complete. Adolescents assigned male at birth appear to be more vulnerable to lasting effects on bone density than those assigned female at birth.
To protect bones during treatment, guidelines strongly recommend at least 1,000 mg of calcium daily through diet, vitamin D supplementation, and regular weight-bearing exercise like running, jumping, or resistance training. These aren’t optional add-ons. They’re a core part of the treatment plan.
Other Side Effects
The most common side effects are localized: soreness, redness, or swelling at injection sites. With the implant, there can be minor scarring or discomfort at the insertion point.
Metabolic changes are also documented. Studies on GnRH agonist therapy show that fat mass can increase while lean body mass decreases, and weight and BMI tend to rise modestly over the first year. These shifts make sense biologically: sex hormones influence how the body distributes fat and builds muscle, so suppressing them changes the balance. Regular physical activity helps counteract these effects.
What Happens When Treatment Stops
Puberty resumes after GnRH agonists are discontinued. In a study tracking children after removal of the histrelin implant, all boys showed spontaneous testicular growth within one year. Among girls treated for precocious puberty, the majority began menstruating within about 12 to 13 months of stopping. The full range is wide, though. Some girls got their first period within two months, while others took up to three years.
For children with precocious puberty, treatment typically continues until around the normal age of puberty (roughly 10 to 11 for girls, 11 to 12 for boys), at which point the medication is stopped and the body picks up where it left off. For transgender adolescents, puberty suppression often serves as a bridge, giving the young person more time before deciding whether to proceed with gender-affirming hormone therapy. If they choose not to proceed, their endogenous puberty will resume on its own.
What Puberty Blockers Don’t Do
GnRH agonists pause future development, but they don’t reverse changes that have already occurred. Breast tissue that has already grown won’t disappear, and a voice that has already deepened won’t get higher. This is why timing matters: treatment is most effective when started early in puberty, before significant changes have taken hold.
These medications also don’t affect gender identity, sexual orientation, or psychological development in any direct way. Their role is purely hormonal, buying time for the child and their family to make decisions without the pressure of a body that’s rapidly changing.